Novavax Introduced Combo Vaccine for COVID-19 and Flu – World Vaccine Congress

Novavax, Public domain, via Wikimedia Commons

Maryland-based vaccine maker Novavax introduced a COVID-19 booster and flu combination vaccine candidate at the World Vaccine Congress in Washington. According to their study, their protein-nanoparticle vaccine Nuvaxoid showed responses against newer variants of the SARS-CoV-2 virus (BA.1, BA.4, and BA.5 of the Omicron variant). This vaccine performed similarly to the immune response of the approved mRNA vaccines. 

The new widely spreading Omicron subvariant XB.1.5 is more advanced and the current vaccines are effective against the earlier strains rather than XB.1.5. The vaccine makers and FDA are working on an updated or next-gen COVID vaccine that could ideally target the variant. 

Source: Novavax


The combination vaccine of Novavax under investigation uses full-length, stabilized recombinant spike (rS) protein of the SARS-Co-2 virus, and wild-type recombinant Hemaggluttin (rHA) proteins from the influenza virus, as antigens. (Source: 

Why Combination Vaccine

Currently, booster doses of vaccines are required at certain time intervals to increase immunity against certain diseases. Simplifying the vaccine shots get more acceptance from people. Novavax also added that COVID-19 may become endemic and therefore require seasonal vaccination, similar to influenza vaccine. 
Source: Novavax

Editor's Desk

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

FDA approves Pfizer's pneumococcal vaccines for children and infants

Mon May 1 , 2023
Pfizer, Team, Public domain, via Wikimedia Commons FDA approves Pfizer’s new pneumococcal vaccines for children and infants on 27th April. The vaccine called Prevenar 20 was made for using against 20 different rate of bacteria. The adult version of the vaccine Prevenar 13 was approved for adults earlier. It is […]

Related Articles